These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 15705644)

  • 1. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
    Steenbergen JN; Alder J; Thorne GM; Tally FP
    J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
    Carpenter CF; Chambers HF
    Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.
    Kanafani ZA; Corey GR
    Expert Rev Anti Infect Ther; 2007 Apr; 5(2):177-84. PubMed ID: 17402833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
    Rybak MJ
    Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daptomycin, a lipopeptide antibiotic in clinical practice.
    Weis F; Beiras-Fernandez A; Schelling G
    Curr Opin Investig Drugs; 2008 Aug; 9(8):879-84. PubMed ID: 18666036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
    Sader HS; Watters AA; Fritsche TR; Jones RN
    BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient].
    Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C
    Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria.
    Johnson A
    Future Microbiol; 2006 Oct; 1(3):255-65. PubMed ID: 17661638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections.
    Kern WV
    Int J Clin Pract; 2006 Mar; 60(3):370-8. PubMed ID: 16494659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD.
    Eisenstein BI; Oleson FB; Baltz RH
    Clin Infect Dis; 2010 Jan; 50 Suppl 1():S10-5. PubMed ID: 20067387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daptomycin: a review 4 years after first approval.
    Sauermann R; Rothenburger M; Graninger W; Joukhadar C
    Pharmacology; 2008; 81(2):79-91. PubMed ID: 17940348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of daptomycin for Staphylococcus aureus infections in critical care medicine.
    Alder J
    Crit Care Clin; 2008 Apr; 24(2):349-63, ix-x. PubMed ID: 18361950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Daptomycin: revitalizing a former drug due to the need of new active agents against grampositive multiresistant bacterias].
    Hernández Martí V; Romá Sánchez E; Salavert Lletí M; Bosó Ribelles V; Poveda Andrés JL
    Rev Esp Quimioter; 2007 Sep; 20(3):261-76. PubMed ID: 18080024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide.
    Sader HS; Streit JM; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2004 Nov; 50(3):201-4. PubMed ID: 15541606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):329-32. PubMed ID: 16263233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
    J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin.
    French GL
    J Antimicrob Chemother; 2006 Dec; 58(6):1107-17. PubMed ID: 17040922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-clinical experience with daptomycin.
    Hawkey PM
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii7-14. PubMed ID: 18829726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin.
    Vikram HR; Havill NL; Koeth LM; Boyce JM
    J Clin Microbiol; 2005 Oct; 43(10):5384-7. PubMed ID: 16208025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004).
    Sader HS; Streit JM; Fritsche TR; Jones RN
    Clin Microbiol Infect; 2006 Sep; 12(9):844-52. PubMed ID: 16882289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.